HPV a\u015f\u0131s\u0131 enfeksiyona kar\u015f\u0131 g\u00fc\u00e7l\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturarak enfeksiyonu \u00f6nler. B\u00f6yle bir a\u015f\u0131 o\u0308zellikle HPV enfeksiyonu riski ta\u015f\u0131yan ki\u015filerde oldukc\u0327a faydal\u0131 olacakt\u0131r. A\u015f\u0131n\u0131n ka\u00e7 y\u0131l s\u00fcre korudu\u011fu kesin olarak bilinmemekle birlikte, koruyuculu\u011fun 5 y\u0131l \u00fczerinde olabilece\u011fi d\u00fc\u015f\u00fcn\u00fclmektedir.<\/p><\/blockquote>\n
HPV nedir?<\/h4>\n
\u0130nsan si\u011fil vir\u00fcs\u00fc<\/em> (HPV<\/em>), rahim a\u011fz\u0131 kanseri<\/em> ve genital si\u011fil<\/em>lere neden olabilen bir vir\u00fcst\u00fcr. HPV kad\u0131nlarda, rahim a\u011fz\u0131 kadar s\u0131k olmamakla birlikte vulva<\/em> (d\u0131\u015f cinsel organ cildi) ve vajina kanseri<\/em>ne de neden olabilirken; hem kad\u0131n hem de erkeklerde an\u00fcs<\/em>, a\u011f\u0131z<\/em> ve bo\u011faz kanseri<\/em> de olu\u015fturabilir.<\/p>\n HPV, cinsel ili\u015fki gibi do\u011frudan cilt temas\u0131 ile bula\u015fan bir vir\u00fcst\u00fcr.<\/p>\n Si\u011fil vir\u00fcs\u00fc, enfekte ki\u015fi ile do\u011frudan temas ile bula\u015f\u0131r. Genital si\u011fil enfeksiyonu cinsel temas ile bula\u015f\u0131r. Cinsel ili\u015fki; vajinal, oral, anal veya el ile temas\u0131n oldu\u011fu b\u00fct\u00fcn cinsel yak\u0131nla\u015fmalar\u0131 i\u00e7erir. Cinsel ili\u015fki olmaks\u0131z\u0131n do\u011frudan ten temas\u0131 ile de bula\u015fma g\u00f6r\u00fclebilir. Cinsel yolla bula\u015fan hastal\u0131klardan korunmada kondom kullan\u0131lmas\u0131 \u00f6nerilmekle birlikte HPV bula\u015fmas\u0131ndan tam korunma sa\u011flayamaz. \u00c7\u00fcnk\u00fc kondom, HPV bulunabilecek cildin t\u00fcm\u00fcn\u00fc kaplamaz.<\/p>\n Cinsel partner say\u0131s\u0131 artt\u0131k\u00e7a HPV ile kar\u015f\u0131la\u015fma riski de artar. Cinsel partnerin \u00f6nceden birlikte oldu\u011fu ki\u015fi say\u0131s\u0131n\u0131n fazla olmas\u0131 da riski art\u0131ran bir fakt\u00f6rd\u00fcr. Hesaplamalara g\u00f6re cinsel olarak aktif yeti\u015fkinler 50 ya\u015f\u0131na geldi\u011finde %75-80 oran\u0131nda HPV ile kar\u015f\u0131la\u015fm\u0131\u015f olacakt\u0131r. 15-25 y\u0131ll\u0131k cinsel temas sonras\u0131 yeti\u015fkinlerin b\u00fcy\u00fck k\u0131sm\u0131nda HPV enfeksiyonu bula\u015fm\u0131\u015f olur.<\/p>\n HPV enfeksiyonu bula\u015fanlar\u0131n \u00e7o\u011funda belirti g\u00f6r\u00fclmez. Bula\u015fma sonras\u0131 v\u00fccut vir\u00fcsten tamamen temizlenebilir. Ancak olgular\u0131n %10-20\u2019sinde vir\u00fcs v\u00fccutta bulunmaya devam edecektir. Bu ki\u015filerde rahim a\u011fz\u0131 kanseri veya kanser \u00f6nc\u00fcl\u00fc lezyonlar\u0131n g\u00f6r\u00fclme olas\u0131l\u0131\u011f\u0131 artar. HPV enfeksiyonundan rahim a\u011fz\u0131 kanseri geli\u015fme s\u00fcresi ortalama 20-25 y\u0131ld\u0131r. Bu nedenle rahim a\u011fz\u0131 kanseri taramas\u0131 i\u00e7in smear yap\u0131lmas\u0131, kanser ba\u015flamadan \u00f6nc\u00fcl lezyonlar\u0131 saptay\u0131p tedavi etmede \u00e7ok b\u00fcy\u00fck \u00f6nem ta\u015f\u0131r.<\/p>\n 100\u2019\u00fcn \u00fczerinde HPV tipi ay\u0131rt edilmi\u015f olup bunlardan 40 kadar\u0131 rahim a\u011fz\u0131n\u0131 enfekte edebilir ve ortalama 15 tanesi rahim a\u011fz\u0131 kanserine neden olabilir. HPV tipleri rahim a\u011fz\u0131 kanseri a\u00e7\u0131s\u0131ndan y\u00fcksek, orta ve d\u00fc\u015f\u00fck riskliler olarak \u00fc\u00e7 gruba ayr\u0131lm\u0131\u015ft\u0131r.<\/p>\n HPV a\u015f\u0131s\u0131, insan papilloma vir\u00fcs\u00fcne (HPV) kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flamak i\u00e7in kullan\u0131lan bir a\u015f\u0131d\u0131r .<\/p>\n A\u015f\u0131lar baz\u0131 ciddi veya \u00f6l\u00fcmc\u00fcl enfeksiyonlar\u0131 \u00f6nleyebilir. V\u00fccudu enfeksiyonlara neden olan mikroplarla sava\u015fmaya haz\u0131rlarlar. Buna a\u015f\u0131lama<\/em> veya ba\u011f\u0131\u015f\u0131klama<\/em>\u00a0denir.<\/p>\n HPV a\u015f\u0131s\u0131 sizi HPV enfeksiyonundan korur. Farkl\u0131 sorunlara yol a\u00e7abilecek farkl\u0131 HPV tipleri vard\u0131r. Baz\u0131 si\u011fil vir\u00fcs\u00fc tipleri ciddi sonu\u00e7lara neden olabilir:<\/p>\n Kad\u0131n i\u00e7 \u00fcreme organlar\u0131<\/p><\/div>\n Genital, an\u00fcs, a\u011f\u0131z veya bo\u011fazda olu\u015fan her si\u011fil vir\u00fcs\u00fc enfeksiyonu kansere yol a\u00e7mayabilir. Asl\u0131nda HPV bula\u015fan ki\u015filerden hangilerinin kanser olaca\u011f\u0131n\u0131 tahmin etmek kolay de\u011fildir. HPV a\u015f\u0131lar\u0131, vir\u00fcs\u00fcn bula\u015fmas\u0131n\u0131 \u00f6nleyerek ilk basamakta korunma sa\u011flam\u0131\u015f olur.<\/p>\n T\u00fcm d\u00fcnyada 3 \u00e7e\u015fit HPV a\u015f\u0131s\u0131 vard\u0131r. A\u015f\u0131lar ve koruduklar\u0131 vir\u00fcs tipleri \u015f\u00f6yle s\u0131ralanabilir.<\/p>\n Gardasil-9<\/strong> (6, 11, 16, 18, 31, 33, 45, 52 ve 58)<\/p>\n Gardasil<\/strong> (6, 11, 16 ve 18)<\/p>\n Cervarix<\/strong> (16 ve 18)<\/p>\n Glaxo Smith Kline<\/em>\u2019\u0131n gelis\u0327tirdig\u0306i as\u0327\u0131 (Cervarix), HPV 16 ve 18 L1 VLP tiplerini ic\u0327erir, FDA taraf\u0131ndan onaylanm\u0131\u015ft\u0131r. \u00c7al\u0131\u015fmalarda Kuzey Amerika, Latin Amerika, Asya ve Avrupa\u2019da 18.000\u2019in \u00fcst\u00fcnde kad\u0131n a\u015f\u0131lanm\u0131\u015ft\u0131r ve 27 ayl\u0131k takip s\u00fcresi ic\u0327inde yeni infeksiyona kar\u015f\u0131 % 92, persistan infeksiyona kar\u015f\u0131 % 100 koruma sag\u0306lam\u0131\u015ft\u0131r. HPV a\u015f\u0131lar\u0131 tipe spesifik oldug\u0306undan, dig\u0306er tiplere kars\u0327\u0131 koruyucu deg\u0306ildir. Sadece HPV 16 ile HPV 31, 33, 58, 18 ile HPV 45 aras\u0131nda no\u0308tralizan epitoplar\u0131n ortak kullan\u0131m\u0131 sonucu c\u0327apraz koruma olmaktad\u0131r. Bu vir\u00fcslerin olu\u015fturabilece\u011fi serviks, vulva, vagina prekanser\u00f6z olu\u015fumlar\u0131n\u0131 ve genital si\u011filleri engellemektedir.<\/p>\n Merck&Co.,Inc<\/em>\u2019\u0131n Gardasil adl\u0131 HPV 6, 11, 16, 18 tiplerini ic\u0327eren a\u015f\u0131s\u0131 ise kuadrivalan bir a\u015f\u0131 olup faz 3 \u00e7al\u0131\u015fmalar\u0131 tamamlanm\u0131s\u0327t\u0131r. Bu 4 tip vir\u00fcs\u00fcn olu\u015fturabilece\u011fi serviks, vulva, vagina prekanser\u00f6z olu\u015fumlar\u0131n\u0131 ve genital si\u011fillerini engellemektedir. Bu a\u015f\u0131 ile 33 \u00fclkede 25.000 kad\u0131n as\u0327\u0131lanm\u0131\u015f ve a\u015f\u0131n\u0131n persistan infeksiyonu o\u0308nlemede % 100 etkili oldug\u0306u go\u0308sterilmis\u0327tir. Ayr\u0131ca Villa ve arkada\u015flar\u0131 \u00e7al\u0131\u015fmalar\u0131nda 15-26 ya\u015f aras\u0131ndaki 12.000 kad\u0131n\u0131 a\u015f\u0131lam\u0131\u015f ve HPV 16\/18\u2019e kar\u015f\u0131 CIN I \/CIN II geli\u015fimini de % 100 o\u0308nledig\u0306ini go\u0308stermi\u015ftir. A\u015f\u0131 3 doz halinde 0, 2 ve 6. aylarda uygulan\u0131r. I\u0307lk cinsel ili\u015fkiden o\u0308nce uyguland\u0131g\u0306\u0131nda % 100\u2019e yak\u0131n koruma sa\u011fland\u0131g\u0306\u0131 vurgulanmaktad\u0131r.<\/p>\n Bu a\u015f\u0131lar\u0131n hepsi g\u00fcvenli ve rahim a\u011fz\u0131 kanserine ilerleyebilecek kanser \u00f6nc\u00fcl\u00fc lezyonlardan koruma konusunda etkilidir. A\u015f\u0131lar\u0131n rahim a\u011fz\u0131 kanseri riskini azaltt\u0131\u011f\u0131, geni\u015f kitlelerde uygulanan \u00e7al\u0131\u015fmalarla g\u00f6sterilmi\u015ftir. Gardasil ve Gardasil-9 yaln\u0131zca rahim a\u011fz\u0131 kanseri de\u011fil, genital si\u011fillerden de %90 oran\u0131nda korunma sa\u011flar.<\/p>\n Si\u011fil vir\u00fcs\u00fc ve \u00f6zellikle de rahim a\u011fz\u0131 kanserinin \u00f6nlenmesi i\u00e7in 2003 y\u0131l\u0131ndan beri piyasada olan a\u015f\u0131lar 2007 y\u0131l\u0131nda \u00fclkemizde de kullan\u0131lmaya ba\u015flanm\u0131\u015ft\u0131r.<\/p>\n HPV A\u015f\u0131lar\u0131yla ilgili TCSB Kanser Dairesi Ba\u015fkanl\u0131\u011f\u0131, FDA (Food and Drug Administration) ve ACIP (Advisory Committee on Immunization Practices) \u00f6nerileri tamamen ayn\u0131d\u0131r. \u0130ki ayr\u0131 firmaya ait HPV a\u015f\u0131s\u0131na ithalat izni verilmi\u015ftir. Bunlardan birisi GSK firmas\u0131na ait ikili a\u015f\u0131 Cervarix\u00ae ve di\u011feri MSD firmas\u0131na ait d\u00f6rtl\u00fc a\u015f\u0131 Gardasil\u00ae\u2019dir. Cervarix’in ithalat\u0131 durmu\u015f olup \u00fclkemiz piyasas\u0131nda yaln\u0131zca Gardasil (4\u2019l\u00fc a\u015f\u0131) bulunmaktad\u0131r.<\/p>\n Baz\u0131 \u00f6zel sa\u011fl\u0131k sigortalar\u0131 d\u0131\u015f\u0131nda geri \u00f6deme kurumlar\u0131 taraf\u0131ndan a\u015f\u0131n\u0131n \u00fccreti \u00f6denmemektedir.<\/p>\n T\u00fcm HPV a\u015f\u0131lar\u0131 koldan enjeksiyon \u015feklinde yap\u0131l\u0131r. A\u015f\u0131 yap\u0131lmas\u0131ndan \u00f6nce muayene veya rahim a\u011fz\u0131 kanseri taramas\u0131 i\u00e7in smear yap\u0131lmas\u0131 gerekli de\u011fildir.<\/p>\n Doz, ya\u015f ve ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin g\u00fcc\u00fcne ba\u011fl\u0131d\u0131r.<\/p>\n En iyi korunma i\u00e7in her \u00fc\u00e7 dozun yap\u0131lmas\u0131 \u00f6nerilir.<\/p>\n HPV a\u015f\u0131s\u0131n\u0131n 11-12 ya\u015flar\u0131nda uygulanmas\u0131 \u00f6nerilir. Ancak 9 ya\u015f\u0131ndan 26 ya\u015f\u0131na kadar a\u015f\u0131 yap\u0131labilir. Hedef 9-26 ya\u015f grubundaki her kad\u0131n\u0131n mu\u0308mku\u0308nse ilk cinsel ili\u015fkiden o\u0308nce, deg\u0306ilse mu\u0308mku\u0308n olan en k\u0131sa zamanda as\u0327\u0131lanmas\u0131d\u0131r. Amerikan \u0130la\u00e7 ve G\u0131da Dairesi (FDA), 26 ya\u015f \u00fczerinde 45 ya\u015f\u0131na kadar a\u015f\u0131 yap\u0131lmas\u0131n\u0131 onaylam\u0131\u015ft\u0131r. Bu ya\u015flarda a\u015f\u0131 yap\u0131lmas\u0131 zararl\u0131 de\u011fildir. \u00d6nceden HPV enfeksiyon al\u0131nm\u0131\u015f ise a\u015f\u0131n\u0131n etkinli\u011fi daha d\u00fc\u015f\u00fck olacakt\u0131r.<\/p>\n HPV a\u015f\u0131lar\u0131, enfeksiyon olu\u015fmadan yap\u0131ld\u0131\u011f\u0131nda en y\u00fcksek etkinlik elde edilebilir. Bu y\u00fczden a\u015f\u0131 ilk cinsel temastan \u00f6nce tamamlanm\u0131\u015f olmal\u0131d\u0131r. A\u015f\u0131lar, \u00f6nceden bula\u015fm\u0131\u015f bir HPV enfeksiyonu veya rahim a\u011fz\u0131nda kanser \u00f6nc\u00fcl\u00fc lezyonlar\u0131n tedavisi i\u00e7in kullan\u0131lmaz.<\/p>\n Genital b\u00f6lgede si\u011fil bulunmas\u0131 veya ge\u00e7irilmi\u015f olmas\u0131, yap\u0131lan smear testinde anormal veya \u015f\u00fcpheli sonu\u00e7lar\u0131n bulunmas\u0131 veya si\u011fil vir\u00fcs\u00fc DNA\u2019s\u0131 saptanm\u0131\u015f olmas\u0131 a\u015f\u0131lama yap\u0131lmas\u0131 i\u00e7in engel de\u011fildir. Ancak a\u015f\u0131dan elde edilecek yarar daha az olacakt\u0131r. Ge\u00e7irilmi\u015f olan enfeksiyon, bir HPV tipine aittir. A\u015f\u0131, di\u011fer HPV tiplerinden korumak i\u00e7in yine de uygulanmal\u0131d\u0131r. A\u015f\u0131 yap\u0131lmadan \u00f6nce ge\u00e7irilmi\u015f olan si\u011filin vir\u00fcs tipi belirlenmesine gerek yoktur.<\/p>\n Baz\u0131 anne babalar \u00e7ocuklar\u0131n\u0131 a\u015f\u0131latmak istemiyorlar. Baz\u0131lar\u0131 a\u015f\u0131 yap\u0131lm\u0131\u015f olman\u0131n sa\u011flad\u0131\u011f\u0131 rahatl\u0131k ile \u00e7ocuklar\u0131n\u0131n cinsel hayat\u0131n\u0131n daha erken ya\u015fta ba\u015flayaca\u011f\u0131ndan endi\u015feleniyor olabilir. Ancak a\u015f\u0131 olanlarda cinsel temas ya\u015f\u0131n\u0131n daha erken oldu\u011funa dair bir bilgi bulunmamaktad\u0131r.<\/p>\n Baz\u0131lar\u0131 a\u015f\u0131n\u0131n ciddi yan etkileri oldu\u011fundan korkarlar. Ancak piyasadaki HPV a\u015f\u0131lar\u0131 \u00fczerinde yap\u0131lan \u00e7al\u0131\u015fmalar g\u00fcvenli olduklar\u0131n\u0131 g\u00f6stermi\u015ftir.<\/p>\n A\u015f\u0131, yap\u0131ld\u0131\u011f\u0131 yerde k\u0131zar\u0131kl\u0131k, \u015fi\u015flik ve a\u011fr\u0131ya neden olabilir.<\/p>\n HPV a\u015f\u0131lar\u0131nda timersol (civa t\u00fcrevi bir koruyucu) kullan\u0131lmamaktad\u0131r.<\/p>\n Uygulama s\u0131ras\u0131nda \u00e7ok nadiren ba\u015f d\u00f6nmesi olabilir. Bu y\u00fczden a\u015f\u0131 yap\u0131l\u0131rken ve yap\u0131ld\u0131ktan sonra bir s\u00fcre oturmal\u0131s\u0131n\u0131z.<\/p>\n Si\u011fil vir\u00fcs\u00fc a\u015f\u0131lar\u0131, vir\u00fcs kaps\u00fcl\u00fcnden \u00fcretilir. Canl\u0131 veya \u00f6l\u00fc vir\u00fcs bulundurmad\u0131\u011f\u0131ndan yan etki olarak HPV enfeksiyonu, HPV ili\u015fkili kanser veya \u00f6l\u00fcme neden olamazlar.<\/p>\n Gebelikte uyguland\u0131\u011f\u0131nda a\u015f\u0131n\u0131n bebek \u00fczerinde bilinen bir risk olu\u015fturdu\u011fu g\u00f6sterilmemi\u015f olmakla birlikte gebelerin a\u015f\u0131lamas\u0131 \u00f6nerilmemektedir. Ancak yine de a\u015f\u0131 yap\u0131lmadan \u00f6nce gebelik testi yap\u0131lmas\u0131 gerekli de\u011fildir. Gebelikte a\u015f\u0131lamaya ba\u015flanmamal\u0131d\u0131r. Gebe kalmadan \u00f6nce a\u015f\u0131lanmas\u0131na ba\u015flanm\u0131\u015f olan bir kad\u0131n\u0131n a\u015f\u0131 dozlar\u0131 gebeli\u011fin bitiminden sonraya ertelenmelidir. \u0130lk doz yap\u0131ld\u0131ktan sonra gebe kal\u0131nd\u0131ysa gebelik sonras\u0131 s\u0131f\u0131rdan ba\u015flanmal\u0131d\u0131r. \u0130ki doz yap\u0131ld\u0131ktan sonra gebelik s\u00f6z konusu ise \u00fc\u00e7\u00fcnc\u00fc doz emzirme d\u00f6neminde do\u011fumdan sonraki 6. haftadan itibaren g\u00fcvenle yap\u0131labilir. Gebe oldu\u011fu bilinmeden a\u015f\u0131 yap\u0131lm\u0131\u015f ise gebeli\u011fin sonland\u0131r\u0131lmas\u0131na gerek yoktur; do\u011fumsal \u00f6z\u00fcr art\u0131\u015f\u0131 g\u00f6sterilmemi\u015ftir. Emzirme s\u0131ras\u0131nda a\u015f\u0131 uygulanmas\u0131nda bir sak\u0131nca bulunmam\u0131\u015ft\u0131r.<\/p>\n A\u015f\u0131, rahim a\u011fz\u0131 ve vajina kanserine neden olabilen HPV enfeksiyonu t\u00fcrlerinin bula\u015fmas\u0131n\u0131 \u00f6nlemede \u00e7ok etkilidir. Di\u011fer kanser t\u00fcrlerinin riskini de azaltabilir. A\u015f\u0131, genital si\u011fillere neden olan HPV t\u00fcrlerini \u00f6nlemede de \u00e7ok etkilidir.<\/p>\n HPV a\u015f\u0131s\u0131 en s\u0131k g\u00f6r\u00fclen tiplere kar\u015f\u0131 geli\u015ftirildi\u011finden t\u00fcm genital kanser ve si\u011fillere kar\u015f\u0131 koruma sa\u011flamaz. HPV a\u015f\u0131s\u0131 rahim a\u011fz\u0131 kanserlerine kar\u015f\u0131 yakla\u015f\u0131k %70,\u00a0 genital si\u011fillere kar\u015f\u0131 yakla\u015f\u0131k %90 oran\u0131nda koruma sa\u011flamaktad\u0131r.<\/p>\n \u00d6nceden HPV bula\u015fm\u0131\u015f olanlarda koruyucu etkisi d\u00fc\u015f\u00fckt\u00fcr ancak yine de uygulanmal\u0131d\u0131r.<\/p>\n A\u015f\u0131 sonras\u0131 koruman\u0131n en az 5 y\u0131l s\u00fcrd\u00fc\u011f\u00fc kan\u0131tlanm\u0131\u015ft\u0131r. Daha uzun s\u00fcreli takip \u00e7al\u0131\u015fmalar\u0131 devam etmektedir. Bu g\u00f6zlemlere g\u00f6re koruma s\u00fcresinin daha uzun bulunaca\u011f\u0131 tahmin edilmektedir. Bug\u00fcnk\u00fc bilgilerin \u0131\u015f\u0131\u011f\u0131nda rapel (tekrar doz) gerekli de\u011fildir.<\/p>\n HPV a\u015f\u0131s\u0131; AIDS, genital u\u00e7uk, klamidya, bel so\u011fuklu\u011fu gibi di\u011fer cinsel yolla bula\u015fan hastal\u0131klardan koruma konusunda etkili de\u011fildir. Genel anlamda cinsel yolla bula\u015fan hastal\u0131klardan korunmak i\u00e7in en iyi yol kondom kullanmakt\u0131r.<\/p>\n HPV a\u015f\u0131s\u0131 yapt\u0131rmak rahim a\u011fz\u0131 kanserine yakalanma riskinizi azalt\u0131r. Ancak sizi tamamen korumaz. A\u015f\u0131 olsan\u0131z da kanser veya kanser \u00f6nc\u00fcs\u00fc hastal\u0131klar i\u00e7in taranmal\u0131s\u0131n\u0131z.<\/p>\n 21 ya\u015f\u0131ndan itibaren smear testi, herkeste oldu\u011fu gibi a\u015f\u0131 yap\u0131lanlarda da yap\u0131lmal\u0131d\u0131r. A\u015f\u0131, yap\u0131lmadan \u00f6nce bula\u015fm\u0131\u015f olabilecek vir\u00fcse ba\u011fl\u0131 riskleri ortadan kald\u0131rmayacakt\u0131r. \u00dcstelik a\u015f\u0131 olanlara da a\u015f\u0131n\u0131n i\u00e7eri\u011finde bulunmayan y\u00fcksek riskli vir\u00fcsler bula\u015fabilir ve kansere neden olabilir.<\/p>\n Rahim a\u011fz\u0131 kanserinin temel \u00f6nlenme yolu kolposkopik muayene ve s\u00fcr\u00fcnt\u00fc testlerinin d\u00fczenli olarak yap\u0131lmas\u0131d\u0131r. Rahim a\u011fz\u0131nda g\u00f6r\u00fclen sorunlar h\u0131zla ve etkin olarak tedavi edilmelidir.<\/p>\n Tarama, Pap test veya rahim a\u011fz\u0131nda aramas\u0131 ile yap\u0131labilir. Pap test, rahim a\u011fz\u0131ndan al\u0131nan s\u00fcr\u00fcnt\u00fcde kanser h\u00fccrelerinin veya kansere d\u00f6n\u00fc\u015febilecek h\u00fccrelerin aranmas\u0131 ile yap\u0131l\u0131r.<\/p>\n HPV a\u015f\u0131lar\u0131 rahim a\u011fz\u0131 kanseri olma riskinizi azalt\u0131r. Ancak risk asla s\u0131f\u0131r de\u011fildir. Bu nedenle rahim a\u011fz\u0131 kanseri taramas\u0131 i\u00e7in smear testlerine devam etmelisiniz.<\/p>\n Y\u00fcksek risk ta\u015f\u0131yanlarda anal ve a\u011f\u0131z, bo\u011faz kanseri tarama y\u00f6ntemleri tan\u0131mlanm\u0131\u015f olmakla birlikte pek \u00e7ok merkezde uygulanamamakta ve rutin taramas\u0131 bulunmamaktad\u0131r.<\/p>\n HPV a\u015f\u0131s\u0131 enfeksiyona kar\u015f\u0131 g\u00fc\u00e7l\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fturarak enfeksiyonu \u00f6nler. B\u00f6yle bir a\u015f\u0131 o\u0308zellikle HPV enfeksiyonu riski ta\u015f\u0131yan ki\u015filerde oldukc\u0327a faydal\u0131 olacakt\u0131r. A\u015f\u0131n\u0131n ka\u00e7 y\u0131l s\u00fcre korudu\u011fu kesin olarak bilinmemekle birlikte, koruyuculu\u011fun 5 y\u0131l \u00fczerinde olabilece\u011fi d\u00fc\u015f\u00fcn\u00fclmektedir. HPV nedir? \u0130nsan si\u011fil vir\u00fcs\u00fc (HPV), rahim a\u011fz\u0131 kanseri ve genital si\u011fillere neden olabilen bir vir\u00fcst\u00fcr. HPV […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[8],"tags":[1043,614,527,235,224,233,225,256],"yoast_head":"\nHPV enfeksiyonu nas\u0131l bula\u015f\u0131r?<\/h4>\n
\n
\u0130nsan papilloma vir\u00fcs\u00fc (HPV) a\u015f\u0131s\u0131 nedir?<\/h4>\n
HPV a\u015f\u0131s\u0131n\u0131 neden yapt\u0131rmal\u0131y\u0131m?<\/h4>\n
\n
![\"Kad\u0131n](\"https:\/\/izmirkarsiyakakadindogummerkezi.com\/wp-content\/uploads\/2021\/02\/Kadingen.jpg\")
Farkl\u0131 HPV a\u015f\u0131lar\u0131 var m\u0131?<\/h4>\n
T\u00fcrkiye’de hangi HPV a\u015f\u0131lar\u0131 var?<\/h4>\n
A\u015f\u0131lar hangi dozda ve ne s\u0131kl\u0131kta yap\u0131l\u0131r?<\/h4>\n
\n
HPV a\u015f\u0131s\u0131 hangi ya\u015fta uygulanmal\u0131d\u0131r?<\/h4>\n
HPV a\u015f\u0131s\u0131n\u0131n yan etkileri nelerdir?<\/h4>\n
HPV a\u015f\u0131s\u0131n\u0131n koruma g\u00fcc\u00fc ne kadard\u0131r?<\/h4>\n
\n
Koruma ne kadar s\u00fcre devam eder?<\/h4>\n
HPV a\u015f\u0131s\u0131 di\u011fer cinsel yolla bula\u015fan hastal\u0131klardan da korur mu?<\/h4>\n
HPV a\u015f\u0131s\u0131 olanlar da rahim a\u011fz\u0131 kanseri taramas\u0131 i\u00e7in smear kontrollerine devam etmeli midir?<\/h4>\n
![\"UpToDate\"](\"https:\/\/izmirkarsiyakakadindogummerkezi.com\/wp-content\/uploads\/2019\/11\/utd.jpg\")
\u00a0Bu sayfa d\u00fczenlenirken\u00a0UpToDate Patient Education<\/em>\u00a0sayfalar\u0131ndan yararlan\u0131lm\u0131\u015ft\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"